
    
      A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group,
      multi-center study to assess the efficacy and safety of glycopyrronium and formoterol
      fumarate inhalation aerosol (GFF; PT003), formoterol fumarate inhalation aerosol (FF; PT005),
      and glycopyrronium inhalation aerosol (GP; PT001) in subjects with moderate to very severe
      COPD, compared with placebo.
    
  